Biospeak: Alzheimer's title

Greetings!

Alzheimer's disease (AD) is a devastating neurological disorder that affects more than 37 million people worldwide. The presence and accumulation of beta-amyloid in the brain, and the self-assembly of hyperphosphorylated tau protein tangles, are thought to contribute to the development and pathogenesis of AD. Although AD has been associated with the presence of neuritic plaques and neurofibrillary tangles in specific brain regions, these symptoms may also be caused by synaptic dysfunction and neuronal loss. The events responsible for triggering this neuronal pathology remain unknown.

This issue of BioSpeak highlights the most recent progress in the area of Alzheimer's research.

Hot topics in Alzheimer's disease research
New genes associated with Alzheimer's disease.
Progress towards therapeutic targets.
Neurotrophins and Alzheimer's disease.
Evidence for toxicity / protective profile of Beta-amyloid oligomers/ monomers.
 New genes associated with Alzheimer's disease

1.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O; the European Alzheimer's Disease Initiative Investigators, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alpérovitch A, Lathrop M, Amouyel P. Nat Genet. 2009 Sep 6. [Epub ahead of print]  Abstract


Progress towards therapeutic targets.

2. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease.
Adlard PA, James SA, Bush AI, Masters CL.Drugs Today (Barc). 2009 Apr;45(4):293-304.
Abstract

3. The role of apolipoprotein E in Alzheimer's disease.
Kim J, Basak JM, Holtzman DM. Neuron. 2009 Aug 13; 63(3):287-303.
Abstract

 Neurotrophins and Alzheimer's disease

4. The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. Knowles JK, Rajadas J, Nguyen TV, Yang T, LeMieux MC, Vander Griend L,
Ishikawa C, Massa SM, Wyss-Coray T, Longo FM. J Neurosci. 2009 Aug 26;29(34):10627-37.
Abstract

Evidence for toxicity / protective profile of Beta-amyloid oligomers/ monomers .
 
5. Beta-amyloid monomers are neuroprotective.
Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A. J Neurosci. 2009 Aug
26;29(34):10582-7.
Abstract

6. Structure-neurotoxicity relationships of amyloid {beta}-protein oligomers.
Ono K, Condron MM, Teplow DB. Proc Natl Acad Sci U S A. 2009 Aug 12. [Epub ahead of print] Abstract



So if you have an Alzheimer's disease reagent related question, email one of our experienced researchers at biospeak@biosensis.com.


Help for researchers from researchers! Our staff have over 60 years experience in manufacturing and using antibodies and have published over 340 peer reviewed research publications.

"Good luck with your research"

Sincerely,
 
Tina!


Have you missed previous issues of BioSpeak? Click Here